雄激素受体剪接变异体7检测方法的研究进展  

Methods for androgen receptor splice variant-7 detection: Advances in studies

作　　者：李坤[1] 范光锐 陈朝虎 王志平[1] LI Kun;FAN Guang-rui;CHEN Chao-hu;WANG Zhi-ping(Research Institute of Urology/Key Laboratory of Gansu Province for Urinary System Diseases/Gansu Provincial Center of Clinical Medicine for Urinary System Diseases,Lanzhou University Second Hospital,Lanzhou,Gansu 730030,China)

机构地区：[1]兰州大学第二医院泌尿外科研究所/甘肃省泌尿系统疾病研究重点实验室/甘肃省泌尿系统疾病临床医学中心

出　　处：《中华男科学杂志》2019年第11期1031-1035,共5页National Journal of Andrology

摘　　要：去势抵抗型前列腺癌(CRPC)治疗方法包括:以紫杉烷为基础的化疗、新型内分泌治疗、免疫疗法和镭233。目前尚无能预测CRPC患者治疗疗效并指导用药的临床生物标志物,大量研究显示雄激素受体剪接变异体(AR-V7)与阿比特龙、恩杂鲁胺耐药相关,而与紫杉烷类药物的耐药不相关,有望成为预测临床疗效、指导用药选择的一种临床实用的肿瘤标志物。然而,AR-V7的检测方法成为其应用于临床的挑战之一。本文就现有的AR-V7检测方法做一综述,并对AR-V7临床应用进行展望,以期推进AR-V7从实验室走向临床。Treatment strategies for castration-resistant prostate cancer(CRPC)mainly include taxane-based chemotherapy,novel endocrine therapy,and immunotherapy with radium 233.At present,there have been no clinical biomarkers for the prediction of the therapeutic effects and guidance with the medication in the treatment of CRPC.A large number of studies have shown that the androgen receptor splice variant-7(AR-V7)is associated with the resistance to abiraterone and enzalutamide but not to Taxanes.So AR-V7 is expected to become a clinically useful tumor marker for predicting the clinical efficacy and guiding medication selection.However,the methods for the detection of AR-V7 present a challenge before its clinical application.This review introduces different methods of AR-V7 detection in the existing studies and looks forward to the clinical application of AR-V7 in order to move AR-V7 from the bench to the bedside.

关 键 词：前列腺癌 去势抵抗型前列腺癌 雄激素受体剪接变异体7(AR-V7) 

分 类 号：R737.25[医药卫生—肿瘤]